Therapy for lower-risk MDS
Lower-risk myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders whe
You're invited to celebrate with us! Find how you can participate here:
Aplastic Anemia Myelodysplastic Syndromes (MDS) Paroxysmal Nocturnal Hemoglobinuria (PNH) Donate
Lower-risk myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders whe
This study investigated the efficacy and safety of azacitidine azacitidine: It works by reducing the amount of methylation in the body.
Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potentially curative option for myelodysplastic syndromes myelodysplast
We conducted a prospective observational study of fit adults aged 60-75 with advanced MDS, enrolled hierarchically for adverse MDS risk (intermediate-2 or high-risk international prognostic score [IPSS], low or intermediate-1 IPSS with poor-risk cytogenetics
Heterogeneity is the disease-defining epithet of myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-ti
The molecular pathogenesis of myelodysplastic syndrome (MDS) is complex due to the high rate of genomic heterogeneity. Significant advances have been made in the last decade which elucidated the landscape of molecular alterations (cytogenetic abnormalities, gene mutations) in MDS.
Treatment with hypomethylating agents (HMAs) azacitidine azacitidine: It works by reducing the amount of methylation in the body.
Patients with myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders